← Leaderboards
Dung-Fang Lee
University Of Texas Hlth Sci Ctr Houston
$2,986,751
Attributed
$2,986,751
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $439.8K · FY2014–25$500K$375K$250K$125K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,986,751 · 3
By mechanism
R01$2,054,629 · 1
R00$729,242 · 1
K99$202,880 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Hlth Sci Ctr Houston
Same institution · by research overlap
- Xiaotian Zhang$1,372,419
Others in their field
Top investigators on “Mutant”
- Kc Kent Lloyd · University Of California At Davis$103,993,616
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Bruce A Beutler · Ut Southwestern Medical Center$34,438,453
- Oscar A. Carretero · Henry Ford Health System$33,594,856
- Stuart H Orkin · Children'S Hospital Boston$33,454,343
- Tracy T Batchelor · Dana-Farber Cancer Inst$31,851,614
Research focus
MutantMolecularMediatingMethodologyMalignant NeoplasmsMalignant Bone NeoplasmGenome-Wide AnalysisGene ExpressionInduced Pluripotent Stem CellIn Vitro ModelLi-Fraumeni SyndromeDown-RegulationLinkBiological ModelsCellsEtiologyFutureCancer EtiologyHuman DiseaseImpairmentInsightInheritedDisease ModelMutation
Grant awards (10)
Dissecting and Targeting RB1-Mutant Osteosarcoma$404,705
R01 · FY2025 · CA · contact PI
Dissecting and Targeting RB1-Mutant Osteosarcoma$384,471
R01 · FY2024 · CA · contact PI
Dissecting and Targeting RB1-Mutant Osteosarcoma$404,808
R01 · FY2023 · CA · contact PI
Dissecting and Targeting RB1-Mutant Osteosarcoma$420,814
R01 · FY2022 · CA · contact PI
Dissecting and Targeting RB1-Mutant Osteosarcoma$439,831
R01 · FY2021 · CA · contact PI
Modeling p53 Mutant-Associated Cancer With LFS Patient-Derived iPSCs$237,098
R00 · FY2018 · CA · contact PI
Modeling p53 Mutant-Associated Cancer With LFS Patient-Derived iPSCs$243,144
R00 · FY2017 · CA · contact PI
Modeling p53 Mutant-Associated Cancer With LFS Patient-Derived iPSCs$249,000
R00 · FY2016 · CA · contact PI
Modeling p53 Mutant-Associated Cancer With LFS Patient-Derived iPSCs$101,520
K99 · FY2015 · CA · contact PI
Modeling p53 Mutant-Associated Cancer With LFS Patient-Derived iPSCs$101,360
K99 · FY2014 · CA · contact PI